<DOC>
	<DOC>NCT02296138</DOC>
	<brief_summary>The overall objective is to assess the effect of once daily tiotropium + olodaterol fixed dose combination compared to 5 µg tiotropium (both delivered with the Respimat® inhaler) on moderate to severe COPD exacerbation in patients with severe to very severe COPD.</brief_summary>
	<brief_title>Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criteria: Male or female patients, 40 years of age or older. Diagnosis of COPD with a documented postbronchodilator Forced expiratory volume in one second (FEV1)&lt; 60% of predicted normal and a postbronchodilator FEV1/FVC (Forced vital capacity) &lt;70% at Visit 1 Documented history of at least one moderate to severe COPD exacerbation in the previous 12 months requiring treatment with systemic corticosteroids and/or antibiotics and/or related hospitalization. Symptomatically stable as defined by: no evidence of COPD exacerbation requiring use of either antibiotics and/or steroids 4 weeks prior to visit 1 and no evidence of change in their usual COPD medication 4 weeks prior to visit 1. Current or exsmokers with a smoking history of more than 10 pack years. Exclusion criteria: Significant disease other than COPD. Clinically relevant abnormal baseline haematology, blood chemistry or creatinine &gt; x2 ULN will be excluded regardless of clinical condition. ( A repeat laboratory evaluation can be conducted if deemed necessary by the investigator.) Current documented diagnosis of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma A diagnosis of thyrotoxicosis A history of myocardial infarction within 6 months of screening visit. Lifethreatening cardiac arrhythmia. Known active tuberculosis. Any malignancy unless free of disease for at least 5 years (patients with treated basal cell carcinoma or squamous cell skin cancers are allowed). A history of cystic fibrosis. Clinically relevant bronchiectasis. Patients with severe emphysema requiring endobronchial interventions within 6 months prior to screening A history of significant alcohol or drug abuse in the opinion of the investigator. Patients who have undergone thoracotomy with pulmonary resection Patients being treated with oral or patch ßadrenergics. Patients being treated with oral corticosteroid medication at unstable doses Patients being treated with antibiotics for any reasons within 4 weeks of screening visit Patients being treated with PDE4 inhibitors within 3 months of screening visit Patients who have taken an investigational drug within one month or six halflives Pregnant or nursing women. Women of childbearing potential not using a highly effective method of birth control.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>